肝硬化患者肌少症的中西医诊疗研究进展

摘要/Abstract

摘要： 肌少症是肝硬化患者营养不良的主要特征,肝硬化患者因蛋白质摄入减少、分解代谢失衡、自身合成不足等原因,患病率较高,同时也是不良预后的关键因素。本病病因复杂,发病机制尚不明确。CT及MRI是量化骨骼肌质量的金标准,能准确地评估切面的肌肉和脂肪含量。传统医学将其归属于“痿证”范畴,病因病机可概括为内外合因和湿浊独胜、湿热蕴胃和寒湿伤脾、肝肾亏虚和肺热津伤、湿化寒浊和君相火弱、久病入络和气滞血瘀5个方面。西医临床以积极治疗原发病、补充营养、运动干预等为主,中医治疗根据辨证论治,予健脾渗湿、平调寒热、滋阴清肺、温阳祛浊、通络化瘀等治法。中西医诊疗可以有效改善肝硬化肌少症患者生存质量并延缓病程进展,因此值得深入研究。

关键词: 肝硬化, 肌少症, 痿证, 中西医诊疗

刘源, 李玉瑶, 鲁冰洁, 钱平安, 聂红明, 沈婷婷. 肝硬化患者肌少症的中西医诊疗研究进展[J]. 肝脏, 2024, 29(9): 1141-1145.

/ 推荐

参考文献

[1] Aand A,Mohta S, Agarwal S,et al. European Working Group on Sarcopenia in Older People (EWGSOP2) criteria with population-based skeletal muscle index best predicts mortality in asians with cirrhosis[J]. J Clin Exp Hepatol,2022,12(1):52-60.
[2] Anker S D, Morley J E, Von Haehling S. Welcome to the ICD-10 code for sarcopenia[J]. J Cachexia Sarcopenia Muscle,2016,7(5):512-514.
[3] 刘永刚,李佳佳,南然,等.肝硬化肌少症中医药诊治思路探讨[J].中华中医药杂志,2023,38(7):3204-3208.
[4] Kuchay M S,Martínez-Montoro J I,Llamoza-Torres C J,et al. Liver cirrhosis and sarcopenia: a dreadful combination[J]. Hepatobiliary Surg Nutr,2022,11(5):729-731.
[5] Nishikawa H,Shiraki M,Hiramatsu A,et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria[J]. Hepatol Res,2016,46(10):951-963.
[6] Tandon P,Montano-Loza A J,Lai J C,et al. Sarcopenia and frailty in decompensated cirrhosis[J]. J Hepatol,2021,75 Suppl 1(Suppl 1):S147-S162.
[7] Dasarathy S,Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol,2016,65(6):1232-1244.
[8] Montano-Loza A J,Duarte-Rojo A,Meza-Junco J,et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol,2015,6(7):e102.
[9] Tantai X,Liu Y,Yeo Y H,et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis[J]. J Hepatol,2022,76(3):588-599.
[10] Zeng X,Shi Z W,Yu J J,et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China[J]. J Cachexia Sarcopenia Muscle,2021,12(6):1948-1958.
[11] Cruz-Jentoft A J,Bahat G,Bauer J,et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing,2019,48(1):16-31.
[12] Kim K M,Jang H C,Lim S. Differences among skeletal muscle mass indices derived from height-,weight-,and body mass index-adjusted models in assessing sarcopenia[J].Korean J Intern Med,2016,31(4):643-650.
[13] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol,2019,70(1):172-193.
[14] Chen L K,Woo J,Assantachai P,et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc,2020,21(3):300-307.e2.
[15] Cui Y,Zhang M,Guo J,et al. Correlation between sarcopenia and cirrhosis: a meta-analysis[J]. Front Nutr,2024,10:1342100.
[16] Nardelli S,Lattanzi B,Merli M,et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology,2019,70(5):1704-1713.
[17] Kumar V V,Kothakota S R,Nair A K,et al. Impact of sarcopenia on post-liver transplant morbidity and mortality in cirrhotic patients[J]. Indian J Gastroenterol,2022,41(5):440-445.
[18] Topan M M,Sporea I,Dănilă M,et al. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis[J]. Front Nutr,2021,8:766451.
[19] 姜雄,何前松,况时祥.况时祥从“毒”论治重症肌无力的临床经验介绍[J].江苏中医药,2016,48(08):19-21.
[20] 胡勇,张惜燕,邢玉瑞,等.叶天士辨治痿证学术思想特色探微[J].吉林中医药,2022,42(6):633-636.
[21] 金子开,郭子为,孙萌,等.朱丹溪痿证诊疗思路探微[J].中国中医基础医学杂志,2021,27(3):386-388.
[22] 罗珺钰,罗耀辉,刘芳,等.罗铨教授对重症肌无力的诊治特色[J].中医临床研究,2022,14(26):69-72.
[23] 何小刚.从脾肾阳虚论治痿证[J].中医药学报,2014,42(3):129-130.
[24] Dent E,Morley J E,Cruz-Jentoft A J,et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening,diagnosis and management[J]. J Nutr Health Aging,2018,22(10):1148-1161.
[25] Tandon P,Ismond K P,Riess K,et al. Exercise in cirrhosis: translating evidence and experience to practice[J]. J Hepatol,2018,69(5):1164-1177.
[26] Duarte-Rojo A,Ruiz-Margáin A,Montaño-Loza A J,et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list[J]. Liver Transpl,2018,24(1):122-139.
[27] Eslamparast T,Montano-Loza A J,Raman M,et al. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans[J]. Liver Int,2018,38(10):1706-1717.
[28] Lai J C,Tandon P,Bernal W,et al. Malnutrition,frailty,and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2021,74(3):1611-1644.
[29] Amodio P,Bemeur C,Butterworth R,et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus[J]. Hepatology,2013,58(1):325-336.
[30] McClave S A,Taylor B E,Martindale R G,et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically Ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)[J]. JPEN J Parenter Enteral Nutr,2016,40(2):159-211.
[31] Plauth M,Bernal W,Dasarathy S,et al. ESPEN guideline on clinical nutrition in liver disease[J]. Clin Nutr,2019,38(2):485-521.
[32] 陶子文,杨长青.肝硬化肌少症的治疗策略及研究方向[J].肝脏,2023,28(6):643-645+653.
[33] Sriram K,Lonchyna V A. Micronutrient supplementation in adult nutrition therapy: practical considerations[J]. JPEN J Parenter Enteral Nutr,2009,33(5):548-562.
[34] Sinclair M,Grossmann M,Hoermann R,et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial[J]. J Hepatol,2016,65(5):906-913.
[35] Kovacheva E L,Hikim A P,Shen R,et al. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin,c-Jun NH2-terminal kinase,Notch,and Akt signaling pathways[J]. Endocrinology,2010,151(2):628-638.
[36] 毛智慧,刘晓亭,孙晓婷,等.刘晓亭运用“脾主肌肉四肢”理论治疗老年肌肉衰减综合征思路浅析[J].辽宁中医杂志,2017,44(7):1407-1409.
[37] 韩行,张林.论风药在痿证治疗中的配伍运用[J].环球中医药,2021,14(10):1863-1865.
[38] 刘灵,高龙霞,李萌,等.基于数据挖掘的《医案类聚》痿证用药规律分析[J].数理医药学杂志,2023,36(2):88-94.
[39] 李盼盼,张林,王芮.论痿证的中医病机及治法研究[J].环球中医药,2018,11(12):1969-1971.
[40] 张子涵,柏久莲,钱玉良.符为民教授论治痿证经验[J].浙江中医药大学学报,2019,43(07):660-663.
[41] 张雅妮,胡华,刘佳,等.《杂病源流犀烛》论治痿证探析[J].中医药临床杂志,2023,35(7):1294-1297.
[42] 许凤全.吴以岭教授从奇经和络脉论治重症肌无力经验撷萃[J].四川中医,2006,(02):4-6.
[43] 张鼎,贾妮,李军.李军应用柴葛二陈桃红四物汤诊治痿证经验[J].吉林中医药,2021,41(8):1022-1024.
[44] 叶铭钢,王键.王任之痿证辨治特色[J].安徽中医学院学报,2011,30(1):16-18.
[45] 张瑜,苏春芝,张桐,等.基于虚劳理论探析肝硬化肌少症[J].河北中医药学报,2023,38(6):33-36.